| Literature DB >> 30394818 |
Yu Zhu1, Chengmao Zhou1, Qixiong He1.
Abstract
OBJECTIVE: To observe the expression and clinical significance of micro RNA (miR)-139-3p in liver cancer tissues, and to explore its relationship with miR-139-3p target genes related to the prognosis of hepatocellular carcinoma (HCC).Entities:
Keywords: The Cancer Genome Atlas; bioinformatics; hepatocellular carcinoma; miR-139-3p; prognosis; target genes
Mesh:
Substances:
Year: 2018 PMID: 30394818 PMCID: PMC6384489 DOI: 10.1177/0300060518802727
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Distribution of miR-139-3p expression and clinical variables in 362 liver cancer patients.
| Clinical variable | All patients (n=362) | Low miR-139-3p expression (n=181) | High miR-139-3p expression (n=181) | P-value |
|---|---|---|---|---|
| Age (years) | 0.058 | |||
| ≤60 | 174 | 78 | 96 | |
| >60 | 188 | 103 | 85 | |
| Sex | 0.175 | |||
| Male | 248 | 118 | 130 | |
| Female | 114 | 63 | 51 | |
| Race | 0.265 | |||
| White | 177 | 92 | 85 | |
| Asian | 158 | 80 | 78 | |
| Other | 18 | 5 | 13 | |
| Unknown | 9 | 4 | 5 | |
| Tumor stage | 0.004 | |||
| 1 | 171 | 70 | 100 | |
| 2 | 83 | 53 | 30 | |
| 3 | 83 | 48 | 35 | |
| 4 | 4 | 2 | 2 | |
| Unknown | 21 | 7 | 14 | |
| T stage | 0.004 | |||
| T1 | 181 | 74 | 107 | |
| T2 | 89 | 57 | 32 | |
| T3 | 78 | 42 | 36 | |
| T4 | 13 | 8 | 5 | |
| Unknown | 1 | 0 | 1 | |
| N stage | 0.784 | |||
| N0 | 249 | 126 | 123 | |
| N1 | 4 | 2 | 2 | |
| NX | 108 | 53 | 55 | |
| Unknown | 1 | 0 | 1 | |
| M stage | 0.370 | |||
| M0 | 264 | 137 | 127 | |
| M1 | 3 | 2 | 1 | |
| MX | 95 | 42 | 53 | |
| Tumor grade | 0.010 | |||
| 1 | 55 | 17 | 38 | |
| 2 | 174 | 87 | 87 | |
| 3 | 120 | 69 | 51 | |
| 4 | 13 | 8 | 5 | |
| Recurrence | 0.114 | |||
| Yes | 171 | 93 | 78 | |
| No | 191 | 88 | 103 |
Figure 1.Kaplan–Meier survival analysis of miR-139-3p expression in liver cancer patients (P<0.01). Blue line indicates low miR-139-3p expression; green line indicates high miR-139-3p expression.
Multivariate Cox proportional hazard analysis of overall liver cancer survival rates.
| Variable | B | SE | Wald | df | Sig. | Exp (B) | 95.0% CI for Exp (B) | |
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Stage | 0.118 | 0.102 | 1.326 | 1 | 0.250 | 1.125 | .921 | 1.374 |
| T | 0.377 | 0.121 | 9.733 | 1 | 0.002 | 1.457 | 1.150 | 1.846 |
| M | 0.231 | 0.106 | 4.801 | 1 | 0.028 | 1.260 | 1.025 | 1.550 |
| miR-139-3p | –0.574 | 0.184 | 9.726 | 1 | 0.002 | 0.563 | 0.393 | 0.808 |
B, regression coefficient; SE, standard error; Wald, chi-square value; df, degrees of freedom; Sig., P-value; Exp (B), relative risk (hazard ratio); CI, confidence interval.
Figure 2.Multivariate Cox survival analysis of miR-139-3p expression in liver cancer patients (covariates: miR-139-3p, T, M). Blue line indicates low miR-139-3p expression; green line indicates high miR-139-3p expression.
Predicted target genes related to the overall survival rates of liver cancer patients.
| Target gene symbol | Gene name | P-value |
|---|---|---|
|
| 1-acylglycerol-3-phosphate O-acyltransferase 3 | 0.0299 |
|
| RAD54 homolog B ( | 0.00377 |
|
| phosphatidylinositol glycan anchor biosynthesis, class S | 0.0445 |
|
| family with sequence similarity 161, member A | 0.0026 |
|
| KIAA0101 | 0.000151 |
|
| Interferon-stimulated 20kDa exonuclease-like 2 | 0.0326 |